Clinical trials: Necrotizing Soft Tissue Infection, open to volunteers
Necrotizing Soft Tissue Infections
Irrigating vs Traditional Negative Pressure Wound Therapy to Treat Necrotizing Soft Tissue Infections
Necrotizing Soft Tissue Infections (NSTIs) are rapidly progressing infections that have a high morbidity and mortality, with the greatest morbidity related to managing the large wounds required to treat these patients.
- Trial name
- NPWT-NSTI (NCT07120386)
- Testing
- Negative Pressure Wound Therapy, Negative Pressure Wound Therapy with Instillation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- HealthPartners Institute
Necrotizing Fascitis, Necrotizing Soft Tissue Infection
The Management of Necrotizing Soft Tissue Infection Wounds With Cytal® Wound Matrix and MicroMatrix®
This is a prospective, pilot, parallel group, randomized controlled trial with 1:1 allocation. This will be a single center study coordinated at the Cleveland Clinic Foundation (CCF) Main Campus in Cleveland, Ohio.
- Trial name
- NCT06857708
- Testing
- Cytal® Wound Matrix, MicroMatrix®
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Benjamin T. Miller
Necrotizing Fascitis
Hyperbaric Oxygen Treatment for Necrotizing Fasciitis and Necrotizing Soft Tissue Infections
The goal of this clinical trial is to learn if hyperbaric oxygen is beneficial in treating necrotizing infections and decreasing rates of morbidity and mortality. This study therefore has two aims: 1.
- Trial name
- NCT07170020
- Testing
- Hyperbaric Oxygen Therapy
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Corewell Health West
Pneumonia, Necrotizing Soft Tissue Infection
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
Our data suggest that modulating the characteristics of light carries the potential to modify the host response to injury and critical illness and thus, improve outcome.
- Conditions
- Pneumonia, Necrotizing Soft Tissue Infection, Intraabdominal Infections, Infection Joint
- Trial name
- NCT03482245
- Testing
- Blue Light
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Washington University School of Medicine
Necrotizing Soft Tissue Infection, Fournier Gangrene
Necrotizing Soft Tissue Infections
SnapNSTI is an international, multicenter, time-bound prospective observational cohort study designed to characterize current epidemiology, management patterns, and outcomes of patients with necrotizing soft-tissue infections…
- Conditions
- Necrotizing Soft Tissue Infection, Fournier Gangrene, Sepsis, Surgical Infection
- Trial name
- SnapNSTI (NCT07107555)
- Where
- Spain
- Volunteers
- 480 people
- Sponsor
- European Society for Trauma and Emergency Surgery
Necrotizing Fascitis
Real-Time Diagnosis of Life-Threatening Necrotizing Soft Tissue Infections (NSTI) Using Indocyanine Green (ICG) Kinetic Modeling
Necrotizing soft-tissue infections (NSTIs, a.k.a. "necrotizing fasciitis" or "flesh-eating bacteria") are aggressive infections that can progress rapidly from mild symptoms to sepsis, multi-organ failure, and death.
- Trial name
- NCT06877793
- Testing
- Administration of indocyanine green (ICG) and fluorescence imaging
- Where
- 8 sites in United States
- Volunteers
- 420 people
- Sponsor
- Eric R. Henderson
Necrotizing Soft Tissue Infection
Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial).
Necrotizing soft-tissue infection (NSTI) is a rare, severe, fast-progressing bacterial infection within the soft tissue compartment. The NSTI mortality rate remain high and largely unaltered in the last decades.
- Trial name
- HOT-NSTI (NCT07489274)
- Testing
- Hyperbaric oxygen treatment, Standard of Care (Investigator Choice)
- Where
- 2 sites in Belgium, Norway
- Volunteers
- 1,480 people
- Sponsor
- Ole Hyldegaard
Necrotizing Soft Tissue Infection
Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections
Necrotizing soft tissue infection (NSTI) is a devastating disease that results in a high rate of in-hospital complications and despite advances in critical care, wound care, and early intervention, NSTI continues to be associated…
- Trial name
- NCT06002607
- Testing
- Antibiotic duration (short course), Antibiotic duration (extended course)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, Irvine
Necrotizing Fascitis, Fournier Gangrene
FATAL-NSTI Study (Factors Associated With In-hospital mortALity in NSTI).
Necrotizing soft tissue infections (NSTIs) are rare but potentially life-threatening infections involving the skin and underlying tissues such as fat, fascia, and sometimes muscle.
- Conditions
- Necrotizing Fascitis, Fournier Gangrene, Fournier's Gangrene, Soft Tissue Infections
- Trial name
- FATAL-NSTI (NCT07359651)
- Testing
- No Intervention: Observational Cohort
- Where
- 4 sites in Italy
- Volunteers
- 300 people
- Sponsor
- University of Cagliari
Necrotizing Soft-tissue Infections
Patients With Necrotizing Skin and Soft Tissue Infections Managed Within the SURFAST Care Pathway.
Necrotising soft-tissue infections (NSTIs) are rare and life-threatening skin and soft tissue infections requiring urgent combined medical and surgical management in specialist centres.
- Trial name
- SURFAST (NCT07417982)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection
Myriad™ Augmented Soft Tissue Reconstruction Registry
This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures.
- Conditions
- Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, Lower Extremity Wound, Pilonidal Sinus
- Trial name
- MASTRR (NCT05243966)
- Testing
- Myriad Matrix™ and Myriad Morcells™
- Where
- 15 sites in United States
- Volunteers
- 800 people
- Sponsor
- Aroa Biosurgery Limited
Tissue Repair, Soft Tissue Reconstruction
Urinary Bladder Matrix (UBM) Registry
The purpose of this registry is to collect real-world information on patients treated with Urinary Bladder Matrix (UBM) products.
- Conditions
- Tissue Repair, Soft Tissue Reconstruction, Wound Management, Pressure Ulcer (PU)
- Trial name
- NCT07805798
- Testing
- Urinary Bladder Matrix (UBM) Products
- Volunteers
- 300 people
- Sponsor
- Integra LifeSciences Corporation